(HealthDay News) — A new open-source platform can accelerate the matching of cancer patients to precision medicine (PM) oncology trials, according to a study published in npj Precision Oncology.
Harry Klein, PhD, from Dana-Farber Cancer Institute in Boston, and colleagues developed MatchMiner, a platform designed to computationally match genomically profiled cancer patients to PM trials.
MatchMiner has 3 modes of use. With the patient-centric mode, clinicians look up a patient to view all trials that are a match for that patient. With the trial-centric mode, clinical trial teams identify patients for PM trials. With trial search, clinicians manually enter search criteria to identify available trials based on external genomic reports.
From March 2016 through March 2021, Dr Klein and colleagues curated 354 PM trials with a broad range of genomic and clinical eligibility criteria, and MatchMiner facilitated 166 trial consents for 159 patients. Patients matched to trials via MatchMiner had a shorter time from the genomic sequencing report date to trial consent (55 days shorter; 22% earlier) than patients consented through non-MatchMiner means.
“With three modes of use, MatchMiner can be used to look up trials for individual patients or to recruit patients for a trial,” the researchers wrote. “MatchMiner can be used with a trial management system to show real-time trial status at the arm level. The combination of real-time trial arm status with detailed genomic eligibility down to the variant level allows MatchMiner to provide highly specific matches to PM trials.”